Diroximel fumarate (DRF)
Evidence-based neurology checklist on diroximel fumarate (drf): Mechanism of action Diroximel fumarate is converted in the gut to the active monomethyl fumarate Gastrointestinal side effects are less frequent than with Dimethyl fumarate Indication Dose Side effects Acronym
Mechanism of action
- Diroximel fumarate is converted in the gut to the active monomethyl fumarate
- Gastrointestinal side effects are less frequent than with Dimethyl fumarate
Indication
Dose
Side effects
Acronym
References
- Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler 2019; 4:1352458519881761.
- Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 Study. CNS Drugs 2020; 34:185-196.
